Retrospective analysis of pediatric patients with Burkitt lymphoma treated in Tanzania following the implementation of the 2016 National Treatment Guidelines: Poor outcomes to current standard‐of‐care therapy
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31145 ↗Kurz gefasst
Leitlinie in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Hutton Chapman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Duke University Hospital, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Burkitt Lymphoma, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Vincristine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute of the National Institutes of Health, Duke Hematology and Transfusion Medicine T32.
Abstract (Originalsprache)
Background
Despite the excellent outcomes achieved in the treatment of pediatric Burkitt lymphoma (BL) in high‐income countries (HICs), outcomes remain poor in low‐ and middle‐income countries (LMICs). Efforts to improve BL outcomes in Tanzania included the creation of National Treatment Guidelines in 2016. However, disease outcomes in Tanzania following the creation of these guidelines have not been reported to date. Procedure Historical records from 2016 to 2021 for patients 0–18 years of age with a diagnosis of BL and seen at Bugando Medical Centre (BMC), in Mwanza, Tanzania, were curated into an electronic database and analyzed descriptively. Patients in this cohort were treated per the Tanzanian National Treatment Guidelines, which include six cycles of cyclophosphamide, vincristine, and methotrexate (COM) chemotherapy with intrathecal methotrexate and cytarabine.
Results
In total, 92 BL patients’ records were eligible for analysis. Patients in this cohort were most commonly Murphy stage II (28%) or stage III (34%). Nearly all, 91%, met International Network for Cancer Treatment and Research (INCTR) high‐risk criteria at presentation. Forty‐two percent of patients did not receive a biopsy and were treated with a presumed diagnosis of BL alone. A 1‐year event‐free survival of 29.6% (95% confidence interval [CI]: 20.3%–39.5%) and a 1‐year overall survival of 38.5% (95% CI: 28%–48.9%) were observed. A high rate of treatment abandonment (34%) was also observed.
Conclusion
In a historical cohort of pediatric patients with BL treated per the 2016 Tanzanian National Treatment Guidelines, we observed poor outcomes and a high rate of abandonment. These outcomes appear inferior to those achieved in the INCTR clinical trial that informed the guidelines’ creation, and highlights the importance of “real‐world” outcomes data in LMICs. These data reinforce the idea that continued clinical research and capacity building efforts are necessary to improve BL outcomes in LMICs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke University Hospital, Durham, North Carolina, USA.
- Duke Global Health Institute, Durham, North Carolina, USA.
- Bugando Medical Centre, Mwanza, Tanzania.
- Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
- Hubert Department of Global Health, Emory University, Atlanta, Georgia, USA.
- Catholic University of Allied and Health Sciences, Mwanza, Tanzania.
ORCID-Profile: Hutton Chapman, Kristin Schroeder
Förderung
- NCI NIH HHS
- National Cancer Institute of the National Institutes of Health
- Duke Hematology and Transfusion Medicine T32
- National Cancer Institute
Zitieren
APA
Chapman, H., Ntemi, P. S., Gisiri, M., Vasudevan, L., Kashaigili, H. J., & Schroeder, K. (2024). Retrospective analysis of pediatric patients with Burkitt lymphoma treated in Tanzania following the implementation of the 2016 National Treatment Guidelines: Poor outcomes to current standard‐of‐care therapy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31145
Vancouver
Chapman H, Ntemi PS, Gisiri M, Vasudevan L, Kashaigili HJ, Schroeder K. Retrospective analysis of pediatric patients with Burkitt lymphoma treated in Tanzania following the implementation of the 2016 National Treatment Guidelines: Poor outcomes to current standard‐of‐care therapy. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31145
BibTeX
@article{Chapman2024,
author = {Chapman, Hutton and Ntemi, Paulo S and Gisiri, Mwitasrobert and Vasudevan, Lavanya and Kashaigili, Heronima J and Schroeder, Kristin},
title = {Retrospective analysis of pediatric patients with Burkitt lymphoma treated in Tanzania following the implementation of the 2016 National Treatment Guidelines: Poor outcomes to current standard‐of‐care therapy},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31145}
}
EUVIMED